Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-K/A
2022 FY
Annual report (amended)
30 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Data from this large safety-trial also published in The Journal of the American College of Cardiology
8 Apr 24
8-K
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
28 Mar 24
8-K
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
21 Mar 24
8-K
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
4 Mar 24
8-K
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
26 Feb 24
8-K
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
26 Dec 23
8-K
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
13 Nov 23
8-K
Company Overview CONFIDENTIAL Atrial Fibrillation Program Update November 2023
13 Nov 23
8-K
Regulation FD Disclosure
7 Nov 23
8-K
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
24 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
28 Feb 24
424B5
Prospectus supplement for primary offering
31 May 23
S-3
Shelf registration
15 May 23
S-8
Registration of securities for employees
28 Apr 23
S-8
Registration of securities for employees
24 Mar 22
S-3
Shelf registration
12 Nov 21
S-3/A
Shelf registration (amended)
28 Oct 21
S-3
Shelf registration
25 Jun 21
S-8
Registration of securities for employees
29 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
PRE 14A
Preliminary proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
5 May 20
DEF 14A
Definitive proxy
5 May 20
Other
EFFECT
Notice of effectiveness
30 May 23
CORRESP
Correspondence with SEC
24 May 23
UPLOAD
Letter from SEC
18 May 23
EFFECT
Notice of effectiveness
3 Feb 22
CORRESP
Correspondence with SEC
31 Jan 22
UPLOAD
Letter from SEC
19 Nov 21
EFFECT
Notice of effectiveness
8 Nov 21
CORRESP
Correspondence with SEC
4 Nov 21
CORRESP
Correspondence with SEC
5 Oct 21
CORRESP
Correspondence with SEC
1 Oct 21
Ownership
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
9 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13D
Alta Fundamental Advisers LLC
9 Nov 23
4
Robert James Wills
9 Jun 23
4
MICHAEL JOHN TOMSICEK
9 Jun 23
4
Richard C Pasternak
9 Jun 23
4
Debra K. Liebert
9 Jun 23